StemCyte was founded with a mission to create the largest, most ethnically diverse Umbilical Cord Bank in the world to serve all patients in need.
Two StemCyte locations were in full operation and increasing its global inventory.
Singapore's Dr. Patrick Tan performed the world's first successful cord blood transplant for Thalassemia Major, and subsequently received a President's Award for his efforts.
StemCyte received AABB accreditation in the USA and Taiwan.
The world’s first Umbilical Cord Blood Transplantation Symposium was hosted by StemCyte at City of Hope National Cancer Hospital in Los Angeles, California.
StemCyte launched its private banking divisions in the USA and Taiwan.
StemCyte Taiwan received the world’s first grant for a non-US public bank and approval from the Taiwan Food and Drug Administration (TFDA) for a Phase II IND clinical trial testing 12 patients diagnosed with Beta-Thalassemia Major.
StemCyte USA received a US Congressional earmark to diversify the United States' public cord bank inventory.
StemCyte is the first cord blood bank to receive accreditation for both Allogeneic and Autologous banking from the Foundation for the Accreditation of Cellular Therapy (FACT).
StemCyte is the first privately owned cord blood bank to become a Health Resources and Services Administration (HRSA) partner.
Two clinical trials were conducted:
The first, chronic stroke patients using autologous peripheral blood stem cells (CD34+). This trial had an 85% success rate.
The second was for the treatment of spinal cord injuries using mononuclear cells from HLA matched CBU from StemCyte’s inventory.
StemCyte applied for a method patent for the modification of cord blood stem cells that are resistant to HIV.
StemCyte conducted phase II spinal cord injury treatment.
StemCyte USA was awarded a U.S. Patent for its unique Plasma Depletion UCB Processing method.
A cord blood collection partnership was established between StemCyte and Sharp Healthcare in San Diego, California.
The second phase spinal cord injury treatment was completed in 2012.
StemCyte received TFDA approval for its Phase II IND clinical trial using CD34+ from patients' peripheral blood for chronic stroke treatment.
During this year, a Chinese patent for the use of Lithium + UCB was awarded to StemCyte.
StemCyte and UC Davis partnered on a public cord blood bank program.
Kaiser and StemCyte partnered to create an innovative model for cord blood collection.
StemCyte applied for a US patent through partner Cell Research Corporation for storing and expanding mesenchymal and epithelial cells for therapeutic products.
StemCyte reached a significant milestone by shipping its 2,000th transplant unit.
StemCyte relocated to a new state-of-the-art facility in Baldwin Park, California.
StemCyte received a patent for Lithium Stimulation of Stem Cells Proliferation and growth factor production.
StemCyte was awarded a Japanese patent for stem cell screening of HIV infection.
StemCyte is the first hybrid cord blood bank to receive FDA approval for a Phase II clinical trial to treat spinal cord injuries.
StemCyte sponsored a Phase I Clinical Trial using cord blood stem cells to treat acute ischemic stroke.
StemCyte announced the successful outcome in Phase I clinical trials in treating Acute Cerebral Stroke using Allogeneic Human Umbilical Cord Blood. The findings were also published in Cell Transplantation in December 2021
StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years.
We Are Proud of Our Accomplishments!
After 25 years in business, StemCyte has emerged as a leader in regenerative medicine.
We are focused on finding a cure to diseases using newborn stem cells.